Yes, I interpretted Dr.Missling to mean just that.
At first I thought that Prof.Macfarlane might have been the key driver in getting the PD trial extended into Australia. Now it looks like Anavex wanted to be sure the Rett AND PD trials achieved full enrollment. It appears the PD trial enrollment might have been slowing after initial good enrollment Also, Rett seems to have needed help with enollment also. I thought it was aleady fully enrolled, as did we not hear that all the enrollees "were on rolodex"?
At any rate I am glad to hear Au is enrolling for these two trials now too. Will help keep the schedule. Good for us, as we are all hoping for results this year!
Prof. Macfarlane may still be a key driver, as his specialties are aged psychiatry and dementia. Glad he is involved.
From several months ago, there was talk of a Rett safety study first, followed by an efficacy study, and questions about young girls being safe with the doses. I think we are seeing that playing out, with the safety and efficacy study for the >18 yr old patients. Later the young girls under 18.
Market Data 
Markets 
AI
